Best treatment options for occult breast cancer: A meta-analysis
暂无分享,去创建一个
[1] Y. Piao,et al. Combined radiotherapy and chemotherapy versus radiotherapy alone in elderly patients with nasopharyngeal carcinoma , 2021, Medicine.
[2] Haidong Zhao,et al. Prognostic significance of occult lymph node metastases in breast cancer: a meta-analysis , 2021, BMC cancer.
[3] K. Moore,et al. Occult breast cancer: Where are we at? , 2020, Breast.
[4] D. Franceschi,et al. The Effect of Hospital Volume on Outcomes of Patients with Occult Breast Cancer , 2020, Annals of Surgical Oncology.
[5] G. Plitas,et al. Axillary Downstaging in Occult Primary Breast Cancer After Neoadjuvant Chemotherapy , 2020, Annals of Surgical Oncology.
[6] Yuxiang Lin,et al. Different Clinicopathological Characteristics and Prognostic Factors for Occult and Non-occult Breast Cancer: Analysis of the SEER Database , 2020, Frontiers in Oncology.
[7] G. Plitas,et al. ASO Author Reflections: Avoiding an Axillary Lymph Node Dissection: The Benefit of Neoadjuvant Chemotherapy for Occult Primary Breast Cancer , 2020, Annals of Surgical Oncology.
[8] L. Prantl,et al. Occult Pathologic Findings in Reduction Mammaplasty in 5781 Patients—An International Multicenter Study , 2020, Journal of clinical medicine.
[9] Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.
[10] F. Macedo,et al. ASO Author Reflections: SLNB with RT May Be Sufficient in Occult Breast Cancer after NAC , 2020, Annals of Surgical Oncology.
[11] R. Mellor. Population analysis , 2020, Nature.
[12] Beiqun Zhao,et al. Treatment for occult breast cancer: A propensity score analysis of the National Cancer Database. , 2019, American Journal of Surgery.
[13] Tae Hyun Kim,et al. Outcome of breast-conserving treatment for axillary lymph node metastasis from occult breast cancer with negative breast MRI , 2019, Breast.
[14] M. McCarter,et al. Analysis of the National Cancer Database Esophageal Squamous Cell Carcinoma in the United States. , 2019, The Annals of thoracic surgery.
[15] W. Irish,et al. The effect of local therapy on breast cancer-specific mortality of women with occult breast cancer and advanced nodal disease (N2/N3): a population analysis , 2019, Breast Cancer Research and Treatment.
[16] D. Toppmeyer,et al. Breast-conservation Therapy After Neoadjuvant Chemotherapy Does Not Compromise 10-Year Breast Cancer–specific Mortality , 2018, American journal of clinical oncology.
[17] S. Xiao,et al. Surgical Management of the Axilla in Breast Cancer Patients with Negative Sentinel Lymph Node: A Method to Reduce False-Negative Rate , 2018, World Journal of Surgery.
[18] G. Di,et al. Clinicopathological characteristics and treatment outcomes of occult breast cancer: a SEER population-based study , 2018, Cancer management and research.
[19] Chanchan Gao,et al. The efficacy and safety of targeted therapy plus fulvestrant in postmenopausal women with hormone-receptor positive advanced breast cancer: A meta-analysis of randomized-control trials , 2018, PloS one.
[20] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[21] Seigo Nakamura,et al. High rate of occult cancer found in prophylactic mastectomy specimens despite thorough presurgical assessment with MRI and ultrasound: findings from the Hereditary Breast and Ovarian Cancer Registration 2016 in Japan , 2018, Breast Cancer Research and Treatment.
[22] H. Iwata,et al. Occult breast cancer may originate from ectopic breast tissue present in axillary lymph nodes , 2018, Breast Cancer Research and Treatment.
[23] P. Yuan,et al. Progress in targeted therapy for breast cancer , 2018, Chronic diseases and translational medicine.
[24] San-Gang Wu,et al. Comparison of survival outcomes of locally advanced breast cancer patients receiving post-mastectomy radiotherapy with and without immediate breast reconstruction: a population-based analysis , 2018, Cancer management and research.
[25] M. Guggenheim,et al. Occurrence of Occult Malignancies in Reduction Mammoplasties , 2018, Front. Surg..
[26] Hao Wu,et al. A retrospective study of optimal surgical management for occult breast carcinoma , 2017, Medicine.
[27] San-Gang Wu,et al. Comparable Survival between Additional Radiotherapy and Local Surgery in Occult Breast Cancer after Axillary Lymph Node Dissection: A Population-based Analysis , 2017, Journal of Cancer.
[28] Xiaoxia Ma,et al. Application of neoadjuvant chemotherapy in occult breast cancer , 2017, Medicine.
[29] S. Feigenberg,et al. Factors Influencing Management and Outcome in Patients with Occult Breast Cancer with Axillary Lymph Node Involvement: Analysis of the National Cancer Database , 2017, Annals of Surgical Oncology.
[30] M. Morrow,et al. Oncologic Outcomes After Treatment for MRI Occult Breast Cancer (pT0N+) , 2017, Annals of Surgical Oncology.
[31] Kyubo Kim,et al. Evaluation of the Benefit of Radiotherapy in Patients with Occult Breast Cancer: A Population-Based Analysis of the SEER Database , 2017, Cancer research and treatment : official journal of Korean Cancer Association.
[32] M. Jacobs,et al. Optimal Surgical Management for Occult Breast Carcinoma: A Meta-analysis , 2016, Annals of Surgical Oncology.
[33] E. Gontier,et al. 18F-FDG PET/CT to Predict Response to Neoadjuvant Chemotherapy and Prognosis in Inflammatory Breast Cancer , 2015, The Journal of Nuclear Medicine.
[34] Bénédicte M A Delattre,et al. PET/MR in Breast Cancer. , 2015, Seminars in nuclear medicine.
[35] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[36] S. Ahn,et al. Treatment and survival of patients with occult breast cancer with axillary lymph node metastasis: A nationwide retrospective study , 2014, Journal of surgical oncology.
[37] S. Ahn,et al. Survival Outcomes of Different Treatment Methods for the Ipsilateral Breast of Occult Breast Cancer Patients with Axillary Lymph Node Metastasis: A Single Center Experience , 2013, Journal of breast cancer.
[38] M. Usel,et al. Breast lesions in reduction mammaplasty specimens: a histopathological pattern in 534 patients , 2013, British Journal of Cancer.
[39] B. Ljung,et al. Breast Cancer, Version 3.2013 , 2013 .
[40] G. Di,et al. Treatment outcomes and unfavorable prognostic factors in patients with occult breast cancer. , 2012, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[41] Donald L. Weaver,et al. Effect of occult metastases on survival in node-negative breast cancer. , 2011, The New England journal of medicine.
[42] W. Woodward,et al. Population‐based analysis of occult primary breast cancer with axillary lymph node metastasis , 2010, Cancer.
[43] P. V. van Diest,et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. , 2009, The New England journal of medicine.
[44] N. Taira,et al. Two cases of occult breast cancer in which PET-CT was helpful in identifying primary tumors , 2008, Breast cancer.
[45] F. Schmidt. Meta-Analysis , 2008 .
[46] S. Edge,et al. Prognosis of Occult Breast Carcinoma Presenting as Isolated Axillary Nodal Metastasis , 2007, Oncology.
[47] S. Iacobelli,et al. Axillary Lymph Node Nanometastases Are Prognostic Factors for Disease-Free Survival and Metastatic Relapse in Breast Cancer Patients , 2006, Clinical Cancer Research.
[48] U. Pietrzyk,et al. Clinical and diagnostic value of preoperative MR mammography and FDG-PET in suspicious breast lesions , 2003, European Radiology.
[49] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[50] J. Bryant,et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. , 2001, Journal of the National Cancer Institute. Monographs.
[51] C. Sweep,et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. , 2001, Journal of the National Cancer Institute.
[52] C. Redmond,et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update , 1983, Cancer.
[53] B. Fornage,et al. Breast Conservation in the Setting of Contemporary Multimodality Treatment Provides Excellent Outcomes for Patients with Occult Primary Breast Cancer , 2014, Annals of Surgical Oncology.
[54] N. Davidson,et al. Adjuvant chemotherapy of axillary lymph-node-positive breast cancer. , 1992, Cancer treatment and research.